Evaxion Biotech (EVAX) Earnings Analysis

Evaxion Biotech (EVAX) next reports earnings on 2026-08-13, consensus EPS -0.01 USD. Last quarter (2026-05-26) it beat with EPS -0.01 USD vs -0.01 USD est (0%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -1.99.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EVAX next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.01 USD
Revenue estimate0.01B

EVAX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-26-0.01 USD-0.01 USD0%Beat
2026-03-05-1 USD-0.245 USD-308.2%Miss
2025-11-060.73 USDn/an/an/a
2025-08-14-0.76 USD-0.5 USD-52%Miss
2025-05-27-0.29 USD-0.65 USD+55.4%Beat
2024-10-31-0.2 USD-0.6 USD+66.7%Beat
2024-08-14-0.6 USD0.1 USD-700%Miss

Beat rate: 3/6 (50%) over reported quarters with consensus data.

EVAX valuation and analyst view

Trailing P/E-1.99
Trailing EPS-1.17023 USD
Price / book1.92
Dividend yield0.00%
Market cap0.02B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target11.5 USD

Related research pages

Frequently asked questions

When is Evaxion Biotech (EVAX)'s next earnings date?

Evaxion Biotech is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.01 USD and revenue estimate of 0.01B.

Did EVAX beat earnings last quarter?

In its 2026-05-26 report, EVAX posted EPS of -0.01 USD versus a -0.01 USD estimate — a beat of 0%.

What is EVAX's earnings track record?

Over the last 6 reported quarters with consensus data, EVAX beat estimates 3 times (50%).

What is EVAX's current P/E ratio and EPS?

EVAX trades at a trailing P/E of -1.99 on trailing EPS of -1.1702336210757156 USD.

What do analysts rate EVAX?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 11.5 USD.